Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy

Journal of the American Society of Nephrology

Volumn 14, Issue 11, 2003, Pages 2843-2850

  Jacobsen, Peter ^a   Tarnow, Lise ^a   Carstensen, Bendix ^a   Hovind, Peter ^a   Poirier, Odette ^b   Parving, Hans Henrik ^a,c  

^a STENO DIABETES CENTER   (Denmark)

^b INSERM   (France)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; CAPTOPRIL; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EDETATE CHROMIUM CR 51; ENALAPRIL; HEMOGLOBIN A1C; INSULIN; LISINOPRIL;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0142151739     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ASN.0000092139.19587.51     Document Type: Article

References (50)

1. Parving H-H, Østerby R, Ritz E: Diabetic nephropathy. In: The Kidney, 6th Ed., edited by Brenner BM, Levine S, Philadelphia, WB Saunders, 2000, pp 1731-1773
2. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving H-H: Progression of diabetic nephropathy. Kidney Int 59: 702-709, 2001.
3. Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study. Br Med J 313: 591-594, 1996
4. Fava S, Azzopardi J, Ellard S, Hattersley AT: ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease. Diabetes Care 24: 2115-2120, 2001
5. Björck S, Blohmé G, Sylvén C, Mulec H: Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant 12: 67-70, 1997
6. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller A, Sackmann H, Bauduceau B, Bled F, Passa P, Alhenc-Gelas F: Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 99: 1585-1595, 1997
7. Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P: Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int 60: 46-54, 2001
8. Hadjadj S, Belloum R, Bouhanick B, Gallois Y, Guilloteau G, Chatellier G, Alhenc-Gelas F, Marre M: Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: A prospective study. J Am Soc Nephrol 12: 541-549, 2001
9. Kimura H, Gejyo F, Suzuki Y, Suzuki S, Miyazaki R, Arakawa M: Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy. Kidney Int 54: 1659-1669, 1998
10. Wong TY, Chan JC, Poon E, Li PK: Lack of association of angiotensin-converting enzyme (DD/II) and angiotensinogen M235T gene polymorphism with renal function among Chinese patients with type II diabetes. Am J Kidney Dis 33: 1064-1070, 1999
11. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel J-M, Corvol P: Molecular basis of human hypertension: Role of angiotensinogen. Cell 71: 169-180, 1992
12. Caulfield M, Lavender P, Farrell M, Munroe P, Lawson M, Turner P, Clark AJL: Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med 330: 1629-1633, 1994
13. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F: Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24: 63-69, 1994
14. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329: 1456-1462, 1993
15. Bröchner-Mortensen J, Rödbro P: Selection of routine method for determination of glomerular filtration rate in adult patients. Scand J Clin Lab Invest 36: 35-45, 1976
16. Feldt-Rasmussen B, Dinesen B, Deckert M: Enzyme immunoassay: An improved determination of urinary albumin in diabetics with incipient nephropathy. Scand J Clin Lab Invest 45: 539-544, 1985
17. Miles DW, Mogensen CE, Gundersen HJG: Radioimmunoassay for urinary albumin using a single antibody. Scand J Clin Lab Invest 26: 5-11, 1970
18. Tarnow L: Diabetic nephropathy. Pathogenetic aspects and cardiovascular risk factors. Dan Med Bull 49: 19-42, 2002
19. Lieberman J, Sastre A: Serum angiotensin-converting enzyme: Elevations in diabetes mellitus. Ann Intern Med 93: 825-826, 1980
20. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Parving H-H: Lack of relationship between an insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 44: 489-494, 1995
21. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346, 1990
22. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, Vlietinck R, Fagard R: The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens 15: 1579-1592, 1997
23. Tarnow L, Gluud C, Parving H-H: Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 13: 1125-1130, 1998
24. Rudberg S, Rasmussen LM, Bangstad HJ, Osterby R: Influence of insertion/deletion polymorphism in the ACE-I gene on the progression of diabetic glomerulopathy in type 1 diabetic patients with microalbuminuria. Diabetes Care 23: 544-548, 2000
25. Solini A, Vestra MD, Saller A, Nosadini R, Crepaldi G, Fioretto P: The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes 51: 251-255, 2002
26. Jacobsen P, Rossing K, Tarnow L, Rossing P, Mallet C, Poirier O, Cambien F, Parving H-H: Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 56: S101-S105, 1999
27. Tomino Y, Makita Y, Shike T, Gohda T, Haneda M, Kikkawa R, Watanabe T, Baba T, Yoshida H: Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron 82: 139-144, 1999
28. Vleming LJ, van der Pijl JW, Lemkes HH, Westendorp RG, Maassen JA, Daha MR, van Es LA, van Kooten C: The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 51: 133-140, 1999
29. Gumprecht J, Zychma MJ, Grzeszczak W, Zukowska-Szczechowska E: Angiotensin I-converting enzyme gene insertion/deletion and angiotensinogen M235T polymorphisms: Risk of chronic renal failure. End-Stage Renal Disease Study Group. Kidney Int 58: 513-519, 2000
30. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, Kubo H, Kawaguchi Y, Kon V, Matsuoka K, Ichikawa I, Sakai O: Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 50: 657-664, 1996
31. Schmidt S, Strojek K, Grzeszczak W, Bergis K, Ritz E: Excess of DD homozygotes in haemodialysed patients with type II diabetes. Nephrol Dial Transplant 12: 427-429, 1997
32. Mitch WE, Walser M, Buffington GA, Lemann J Jr: A simple method of estimating progression of chronic renal failure. Lancet 2: 1326-1328, 1976
33. Jones RH, Hayakawa H, Mackay JD, Parsons V, Watkins PJ: Progression of diabetic nephropathy. Lancet 1: 1105-1106, 1979
34. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR: A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 20: 457-461, 1981
35. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330: 877-884, 1994
36. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352: 1252-1256, 1998
37. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
38. Greene T, Lau J, Levey AS: Immunological Renal Diseases. Edited by Nelson EG, Couser WG, Philadelphia, PA, Lippincott Williams & Wilkins, 1997, pp 887-911
39. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G: Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364, 1999
40. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, Klahr S: Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 10: 2426-2439, 1999
41. Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA: Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J 294: 1443-1447, 1987
42. Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ: Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 31: 379-384, 2002
43. Pei Y, Scholey J, Thai K, Suzuki M, Cattran D: Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients. J Clin Invest 100: 814-820, 1997
44. Jackson B, Johnston CI: Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension. Clin Exp Pharmacol Physiol 11: 355-359, 1984
45. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ: Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens 13: 1602-1609, 1995
46. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P, Nystrom F, Hagg A, Lind L: Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 20: 657-663, 2002
47. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Lecerf L, Poirier O, Danilov S, Boelskifte S, Borch-Johnsen K, Parving H-H: Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 38: 798-803, 1995
48. Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delepine M, Lathrop M, Peto R, Collins R: Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 355: 434-442, 2000
49. Sethi AA, Tybjaerg-Hansen A, Gronholdt ML, Steffensen R, Schnohr P, Nordestgaard BG: Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. Six case-control studies from the Copenhagen City Heart Study. Ann Intern Med 134: 941-954, 2001
50. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F, Ducimetiere P: Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 344: 910-913, 1994